-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tecovirimat in Monkeypox
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tecovirimat in Monkeypox report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tecovirimat in Monkeypox Drug Details: Tecovirimat (Tpoxx / ST-246) is an antiviral...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rintatolimod in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rintatolimod in Metastatic Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rintatolimod in Metastatic Colorectal Cancer Drug Details: Ampligen is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tazemetostat Hydrobromide in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tazemetostat Hydrobromide in Transitional Cell Carcinoma (Urothelial Cell Carcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tazemetostat Hydrobromide in Transitional Cell Carcinoma (Urothelial...
-
Product Insights
NewMonkeypox – Drugs In Development, 2024
Empower your strategies with our Monkeypox – Drugs In Development, 2024 report and make more profitable business decisions. Mpox, caused by the monkeypox virus, is an infectious disease presenting with a painful rash, fever, and enlarged lymph nodes. While most individuals fully recover, some may experience severe illness. Person-to-person transmission occurs through direct contact with infectious skin or lesions, including those in the mouth or genitals. Symptoms manifest from 1-21 days after exposure, lasting 2-4 weeks or longer in individuals with...
-
Product Insights
NewSmallpox – Drugs In Development, 2024
Empower your strategies with our Smallpox – Drugs In Development, 2024 report and make more profitable business decisions. Smallpox was an acute contagious infection caused by the Variola virus. Symptoms include fever, malaise, headache, prostration, severe back pain, abdominal pain, and vomiting. This is followed by the development of rashes on the face, hands, forearms and the trunk. Lesions develop in the mucous membranes of the nose and mouth which ulcerate, releasing large amounts of virus into the mouth and throat....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MRNA-1010 in Seasonal Influenza
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MRNA-1010 in Seasonal Influenza report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MRNA-1010 in Seasonal Influenza Drug Details: mRNA-1010 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AD-218 in Mixed Dyslipidemia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.AD-218 in Mixed Dyslipidemia Drug Details:AD-218 is under development for the treatment of hyperlipidemia and mixed...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – mRNA-1030 in Seasonal Influenza
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.MRNA-1030 in Seasonal Influenza Drug Details:mRNA-1030 is under development for the prevention of seasonal influenza, including...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tecovirimat in Monkeypox
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tecovirimat in Monkeypox report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tecovirimat in Monkeypox Drug Details: Tecovirimat (Tpoxx / ST-246) is an antiviral...
-
Company Insights
Innovation and Patenting activity of SIGA Technologies Inc Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of SIGA Technologies Inc Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...